Spots Global Cancer Trial Database for Study of IMC-11F8 in Patients With Tumors Who Have Not Responded to Standard Therapy
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of IMC-11F8 in Patients With Tumors Who Have Not Responded to Standard Therapy
Official Title: Phase I Study of the Fully Human Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody IMC-11F8 in Patients With Solid Tumors Who Have Failed Standard Therapy
Study ID: NCT00801177
Conditions
Study Description
Brief Summary: The purpose of this study is to determine if IMC-11F8 is safe for patients, and also to determine the best dose of IMC-11F8 to give to patients.
Detailed Description: The purpose of this study is to establish the safety profile and the maximum tolerated dose (MTD) of the fully human anti-EGFR monoclonal antibody IMC-11F8 in patients with solid tumors who have filed standard therapy or for whom no standard therapy is available.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
ImClone Investigational Site, Amsterdam, , Netherlands
ImClone Investigational Site, Utrecht, , Netherlands
Contact Details
Name: E-mail: ClinicalTrials@ ImClone.com
Affiliation: Eli Lilly and Company
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
